Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Net Cash Flow (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Net Cash Flow for 2 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 666.57% to $33.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $82.3 million through Dec 2025, up 661.5% year-over-year, with the annual reading at $82.3 million for FY2025, 662.98% up from the prior year.
  • Net Cash Flow hit $33.8 million in Q4 2025 for Xilio Therapeutics, up from -$17.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $40.0 million in Q2 2024 to a low of -$17.8 million in Q3 2025.